Bristol-Myers Squibb (BMY) Highlights Significant Benefits of Pending Transaction with Celgene (CELG)

March 19, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Mergers and Acquisitions

Next Articles